mm-121
Showing 1 - 10 of 10
NSCLC, NSCLC, Adenocarcinoma Trial in Worldwide (MM-121, Docetaxel)
Terminated
- Non-Small Cell Lung Cancer
- +3 more
- MM-121
- Docetaxel
-
Tucson, Arizona
- +34 more
Oct 11, 2021
Colorectal Cancer, Squamous Cell Head Neck Cancer, NSCLC Trial in United States (MM-121, Irinotecan, Cetuximab)
Completed
- Colorectal Cancer
- +4 more
- MM-121
- +2 more
-
San Francisco, California
- +3 more
Sep 6, 2016
Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,, Primary Peritoneal Cancer or Endometrial
Completed
- Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,
- +2 more
- MM-121
- Paclitaxel
-
Birmingham, Alabama
- +4 more
Sep 6, 2016
NSCLC Trial in Worldwide (MM-121, Erlotinib)
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer Trial in United States (MM-121, Paclitaxel)
Completed
- Epithelial Ovarian Cancer
- +2 more
- MM-121
- Paclitaxel
-
Glendale, Arizona
- +9 more
Apr 11, 2016
Her2 Negative Breast Cancer Patients Trial in Worldwide (MM-121, Placebo, Exemestane)
Completed
- Her2 Negative Breast Cancer Patients
- MM-121
- +2 more
-
Birmingham, Alabama
- +32 more
Apr 11, 2016
ER Positive, Her2 Negative Breast Cancer Patients, Triple Negative Breast Cancer Patients Trial in United States (MM-121,
Completed
- ER Positive, Her2 Negative Breast Cancer Patients
- Triple Negative Breast Cancer Patients
- MM-121
- Paclitaxel
-
Birmingham, Alabama
- +37 more
Mar 30, 2016